Posted by

WITHOUT REMISSION, THE BURDEN OF MDD GROWS

For 50 years, pharmacological treatment approaches in MDD have focused on targeting monoamine receptors in the hopes of reducing symptoms. While conventional therapies have helped many, the STAR*D trial* revealed that as many as a third of patients may not achieve remission despite treatment with traditional antidepressants.¹,² Dr Rakesh Jain, clinical professor of psychiatry at […]

Posted by
Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings

Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings

Key Points Question  What are the trends across adulterated dietary supplements associated with a warning released by the US Food and Drug Administration from 2007 through 2016? Findings  In this quality improvement study, analysis of the US Food and Drug Administration warnings from 2007 through 2016 showed that unapproved pharmaceutical ingredients were identified in 776 dietary supplements, […]

Posted by
Precision Medicine:The Future is Coming Fast

Precision Medicine:The Future is Coming Fast

Promise of Precision Medicine in Psychiatry Nears Reality BARCELONA, Spain — Innovative approaches and widespread data sharing are essential in psychiatry to improve patient care and deliver on the long-held promise of precision medicine, a leading European expert says. In a plenary lecture delivered here at the 31st European College of Neuropsychopharmacology (ECNP) Congress, Marion […]

Posted by

The APA Brings Genetic Testing Under Fire, Genomind and Genesight Respond

On April 25th 2018 the American Psychiatric Association published the following criticism of genomic testing emphasizing their skepticism towards psychiatrists who are using genetic testing to make informed decisions about diagnosis and treatment. An abstract of their statement reads:       Evidence Does Not Support Commercial Rush Of DNA Tests Designed To Inform Decisions […]

Posted by
Is the Ketamine Boom Getting out of Hand? A Response.

Is the Ketamine Boom Getting out of Hand? A Response.

On September 26 2018 Scientific American published an article calling out some of the business practices being used by ketamine treatment providers across the country. The article summarized legitimate concerns about the business side of the ketamine while reiterating the promise ketamine shows as a breakthrough treatment for difficult to treat cases of depression. “This […]

Posted by
Brexanolone Infusion Rapidly Relieves Postpartum Depression

Brexanolone Infusion Rapidly Relieves Postpartum Depression

NEW YORK (Reuters Health) – A 60-hour infusion of brexanolone significantly improves symptoms in women with postpartum depression, according to results from two phase 3 trials. The results “confirm and extend the previous work showing that brexanolone has a rapid onset of action that is unlike anything else currently available,” said Dr. Samantha Meltzer-Brody from […]

Posted by
A Deeper Understanding of Major Depressive Disorder is Within Reach

A Deeper Understanding of Major Depressive Disorder is Within Reach

WHY AREN’T SOME PATIENTS WITH MDD REACHING REMISSION? For more than 50 years, major depressive disorder (MDD) pharmacological treatment approaches have focused on increasing the level of monoamine neurotransmitters in the brain, with the hope of reducing symptoms.1 And while conventional antidepressants have helped most, the STAR*D trial* found that one-third of patients didn’t achieve remission after multiple treatment […]

Posted by

MDD and the Role of Neuroplasticity

Impaired Synaptic Connections Research increasingly links impaired synaptic connections with MDD.1 Synaptic connections are constantly remodeled, created, and lost as a result of new experiences, emotions, learning, and memory.1 However, this synaptic plasticity may be impaired in patients with MDD.2 In a study published in Nature Medicine, researchers found a significantly lower number of synapses in key regions of post-mortem […]

Posted by

The Glutamate Hypothesis in Synaptic Connectivity

Glutamate neurotransmission is an active area of research in major depressive disorder (MDD).1 Much of this interest revolves around glutamate’s role in regulating synaptic connectivity, one of several pathways that may strengthen and initiate the formation of new synaptic connections.1 As research advances, a deeper understanding of MDD is within reach. Watch our video featuring Dr […]